Pyrostig60 mg

Pyrostig is a reversible acetylcholinesterase inhibitor with the following evidence-based uses:

Established / FDA-approved uses

• Symptomatic treatment of myasthenia gravis: Pyrostig is the first-line acetylcholinesterase inhibitor used to improve muscle strength and reduce fatigability in patients with myasthenia gravis. It treats symptoms but does not alter the underlying autoimmune disease process.
• Reversal of the effects of non-depolarizing neuromuscular blocking agents: the injectable form of Pyrostig is used after surgery to reverse residual neuromuscular blockade caused by non-depolarizing muscle relaxants, and is administered together with an antimuscarinic agent (such as atropine or glycopyrrolate) to control muscarinic side effects.

Guideline-supported / commonly recognized off-label use

• Congenital and transient neonatal myasthenic syndromes: oral Pyrostig (often as syrup) is commonly used, guided by a specialist, although formal pediatric labeling is limited.

Pyrostig is a symptomatic treatment; it does not cure myasthenia gravis and is often combined with other immunomodulating therapies as directed by a physician.

Each tablet/dose contains Pyridostigmine Bromide as the active pharmaceutical ingredient. Pyridostigmine Bromide is available as conventional tablets, extended-release tablets, oral syrup, and an injectable solution, depending on the manufacturer and market.

Pyrostig is a synthetic, reversible acetylcholinesterase (cholinesterase) inhibitor belonging to the carbamate class of cholinergic agents. It is structurally and pharmacologically related to neostigmine but has a longer duration of action and, because it is a quaternary ammonium compound, does not readily cross the blood-brain barrier, which limits central nervous system effects.

Pyrostig is used mainly for the symptomatic management of myasthenia gravis and, in injectable form, for reversal of non-depolarizing neuromuscular blockade after anesthesia.

Pyrostig belongs to the therapeutic class of anticholinesterase (acetylcholinesterase inhibitor) agents, specifically the carbamate-type cholinergic agonists used in neuromuscular disorders.

Mechanism of action: Pyridostigmine Bromide reversibly inhibits the enzyme acetylcholinesterase at the neuromuscular junction and at other cholinergic synapses, preventing the breakdown of acetylcholine. This increases the concentration and prolongs the action of acetylcholine, enhancing cholinergic transmission at nicotinic receptors of skeletal muscle and improving muscle strength and endurance in myasthenia gravis. It also increases acetylcholine effects at muscarinic receptors (smooth muscle, glands, heart), which accounts for many of its side effects.

Pharmacokinetics

• Absorption: oral bioavailability is low and variable (roughly 10-20%); onset of action after oral dosing is about 30-60 minutes.
• Duration of action: approximately 3-6 hours for standard-release tablets/syrup; longer (up to about 6-12 hours) for the extended-release formulation.
• Distribution: as a quaternary ammonium compound, Pyridostigmine Bromide has limited penetration across the blood-brain barrier.
• Metabolism: partly hydrolyzed by cholinesterases and partly metabolized hepatically.
• Excretion: primarily renal, largely as unchanged drug and metabolites; elimination half-life is approximately 3-4 hours (may be prolonged in renal impairment).

Pyrostig tablets and syrup are usually taken orally, ideally at consistent times relative to meals as advised by the prescriber, to help control fluctuating muscle weakness throughout the day. Extended-release tablets are swallowed whole. The injectable form of Pyrostig is given intravenously only by trained medical personnel in a hospital/surgical setting.

The following are well-established, clinically significant interactions with Pyrostig:

• Other cholinesterase inhibitors (e.g., other anticholinesterase drugs, some pesticides/organophosphates): concurrent use increases the risk of additive cholinergic toxicity (cholinergic crisis). Avoid unless directed by a specialist.
• Neuromuscular blocking agents: Pyrostig antagonizes the effect of non-depolarizing muscle relaxants (its intended clinical use for reversal) but may prolong and intensify the neuromuscular blockade produced by depolarizing agents such as succinylcholine. Anesthesia providers must be informed if a patient is taking Pyrostig.
• Atropine and other anticholinergic/antimuscarinic drugs: can mask early muscarinic warning signs of Pyrostig overdose (e.g., abdominal cramping, excess salivation), potentially delaying recognition of cholinergic crisis.
• Aminoglycoside antibiotics, magnesium salts, procainamide, quinidine, and certain other antiarrhythmics: may impair neuromuscular transmission and antagonize the therapeutic effect of Pyrostig, potentially worsening myasthenic weakness.
• Corticosteroids: when corticosteroid therapy is initiated in a patient on Pyrostig, a transient worsening of myasthenic weakness has been reported; close monitoring is advised during this period.
• Beta-blockers: may have additive effects on cardiac conduction (bradycardia) when combined with the muscarinic effects of Pyrostig.

Always inform your physician, surgeon, and anesthesiologist about all medicines you are taking before starting or stopping Pyrostig, or before any surgical procedure.

Side effects of Pyrostig are generally dose-related and result from excess cholinergic stimulation.

Common

• Nausea, vomiting, diarrhea, abdominal cramping
• Increased salivation and sweating
• Increased bronchial and gastrointestinal secretions
• Miosis (pupil constriction) and blurred vision

Less common / dose-related, requiring prompt attention

• Muscle fasciculations, cramps, or weakness (can indicate overdose - see Overdose)
• Bradycardia (slow heart rate) or other changes in heart rhythm
• Bronchospasm, particularly in patients with asthma/COPD (see Precautions)

Seek prompt medical attention for severe abdominal pain, marked increase in weakness, breathing difficulty, or significant slowing of the heart rate.

Pregnancy: Data on Pyrostig use in human pregnancy are limited. Myasthenia gravis itself may worsen or fluctuate during pregnancy, and untreated maternal myasthenic weakness carries its own risks, so Pyrostig is often continued when clearly needed for maternal disease control. Pyrostig should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under the guidance of a physician experienced in managing myasthenia gravis in pregnancy.

Lactation: Pyrostig is excreted in breast milk in small amounts. Because infants have immature drug clearance, breastfeeding while taking Pyrostig should be discussed with a physician, weighing the benefits of breastfeeding against the limited safety data, with the infant monitored for any cholinergic symptoms.

Do not start or stop Pyrostig during pregnancy or breastfeeding without consulting your physician.

• Cholinergic crisis: overdose of Pyrostig can cause a cholinergic crisis from excessive muscarinic and nicotinic stimulation. This can be difficult to distinguish clinically from a myasthenic crisis (worsening of the underlying disease/under-treatment) because both can present with increasing muscle weakness, yet they require opposite treatment approaches. Any unexplained worsening of weakness while on Pyrostig requires prompt medical evaluation. See also Overdose Effects.
• Asthma or COPD: Pyrostig can increase bronchial secretions and provoke bronchospasm; use with caution and close monitoring in patients with reactive airway disease.
• Bradycardia or cardiac arrhythmias: Pyrostig's cholinergic effect can slow heart rate or precipitate conduction disturbances; use with caution in patients with pre-existing cardiac rhythm problems.
• Parkinson's disease: cholinergic stimulation may worsen parkinsonian symptoms; use with caution.
• Peptic ulcer disease: Pyrostig increases gastric acid secretion and gastrointestinal motility and may aggravate peptic ulcer disease.
• Individualized, specialist-guided dosing: the correct dose of Pyrostig varies widely between patients and over time within the same patient; dosing should be titrated only by, or under close direction of, a physician experienced in myasthenia gravis management.
• Perioperative/anesthesia coordination: concurrent use of Pyrostig with other cholinesterase-affecting drugs or neuromuscular blocking agents requires careful coordination with the anesthesia and surgical team.
• Renal impairment: since Pyrostig is largely excreted renally, patients with kidney impairment may need lower doses and closer monitoring.

Overdose of Pyrostig can cause a cholinergic crisis due to excessive stimulation of muscarinic and nicotinic receptors. Symptoms may include increased salivation, sweating, lacrimation, abdominal cramping, nausea, vomiting, diarrhea, miosis, bradycardia, and progressive muscle weakness that can affect breathing muscles.

Because cholinergic crisis symptoms can resemble worsening myasthenia gravis (myasthenic crisis) but require different management, suspected overdose is a medical emergency. If overdose is suspected, seek immediate medical attention or contact emergency services/poison control right away; do not attempt to self-treat or adjust the dose at home. Hospital management may include temporarily stopping Pyrostig, supportive respiratory care, and administration of an antimuscarinic agent such as atropine under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric use: Pyrostig is used off-label, under specialist supervision, for congenital and transient neonatal myasthenic syndromes; formal safety and efficacy data in children are limited, and dosing must be individualized by a pediatric specialist.
• Elderly: use with caution; age-related decline in renal function may require dose adjustment and closer monitoring for cholinergic side effects, as Pyrostig is largely renally excreted.
• Renal impairment: dose reduction and careful monitoring are recommended, since Pyrostig clearance is reduced when kidney function is impaired.
• Hepatic impairment: specific dose adjustment data are limited; use with caution and clinical monitoring.
• Pregnancy and lactation: see Pregnancy and Lactation section.
• Patients with asthma/COPD, cardiac arrhythmia, Parkinson's disease, or peptic ulcer disease: see Precautions and Warnings.

Pyrostig is typically used long-term (often lifelong) for the symptomatic control of myasthenia gravis, with the dose adjusted over time as disease activity changes. For reversal of neuromuscular blockade, it is used as a single perioperative dose. Duration of oral therapy should be determined and periodically reviewed by the treating physician.

Pyridostigmine Bromide is classified as a cholinergic agent, specifically a reversible (carbamate-type) acetylcholinesterase inhibitor.

Pyridostigmine Bromide reversibly binds to and inhibits acetylcholinesterase, the enzyme responsible for breaking down acetylcholine at cholinergic synapses. By blocking this breakdown, Pyridostigmine Bromide increases the amount and prolongs the action of acetylcholine at the neuromuscular junction, enhancing neuromuscular transmission and improving muscle strength in myasthenia gravis; it also enhances acetylcholine action at muscarinic receptors elsewhere in the body.

C

Pyrostig is not formally approved for a specific age range in most product labeling, but it is commonly used off-label, under the direction of a pediatric neurology or neuromuscular specialist, for congenital myasthenic syndromes and transient neonatal myasthenia gravis (weakness in infants born to mothers with myasthenia gravis due to transplacental antibody transfer). Dosing in children is individualized based on age, body weight, and clinical response, often starting with the oral syrup formulation. Safety and efficacy of Pyrostig in the general pediatric population have not been formally established through large controlled trials, so pediatric use should always be supervised by a specialist familiar with these rare conditions.